Publications:

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.

Translational Cancer Research

Hu, Han H; Dai, Hui H; Ding, Liren L

Publication Date: 2022-08

Variant appearance in text: ALK: E1129V

PubMed Link: 36093526

Variant Present in the following documents:

• Main text
• tcr-11-08-2967.pdf

View BVdb publication page

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.

Ebiomedicine

Dietz, Steffen S; Christopoulos, Petros P; Yuan, Zhao Z; Angeles, Arlou Kristina AK; Gu, Lisa L; Volckmar, Anna-Lena AL; Ogrodnik, Simon J SJ; Janke, Florian F; Fratte, Chiara Dalle CD; Zemojtel, Tomasz T; Schneider, Marc A MA; Kazdal, Daniel D; Endris, Volker V; Meister, Michael M; Muley, Thomas T; Cecchin, Erika E; Reck, Martin M; Schlesner, Matthias M; Thomas, Michael M; Stenzinger, Albrecht A; Sültmann, Holger H

Publication Date: 2020-12

Variant appearance in text: ALK: E1129V

PubMed Link: 33161228

Variant Present in the following documents:

• Main text
• main.pdf
• mmc1.pdf

View BVdb publication page

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Drug Design, Development And Therapy

Santarpia, Mariacarmela M; Daffinà, Maria Grazia MG; D'Aveni, Alessandro A; Marabello, Grazia G; Liguori, Alessia A; Giovannetti, Elisa E; Karachaliou, Niki N; Gonzalez Cao, Maria M; Rosell, Rafael R; Altavilla, Giuseppe G

Publication Date: 2017

Variant appearance in text: ALK: E1129V

PubMed Link: 28740365

Variant Present in the following documents:

• Main text
• dddt-11-2047.pdf

View BVdb publication page